Figures computed from official regulatory filings — .
Analysttarget 8.06 USD (+698%) · consensus 5/5 · 2 buy · 0 hold · 0 sell
Ownershipinsiders 47.65% · institutions 1.91% · short 7.3% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Tiziana Life Sciences Ltd only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
5 buysbar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Elrifi Ivor | ExerciseD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Elrifi Ivor | Exercise | n/a (No price was disclosed in the filing) | SEC |
| CERRONE GABRIELE Mtrack record | Buy | $41.9K | conv 29 | SEC |
| CERRONE GABRIELE Mtrack record | Buy | $16.7K | conv 29 | SEC |
| Elrifi Ivor | Buy | $237.6K | conv 54 | SEC |
| Elrifi Ivor | Buy | $81.3K | conv 52 | SEC |
| Elrifi Ivor | Buy | $667K | conv 66First in 12mo | SEC |